Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.72bn
- Net income in CHF654.00m
- Incorporated2002
- Employees18.00k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
Mergers & acquisitions
Acquired company | LONN:SWX since announced | Transaction value |
---|---|---|
Genentech Inc-Biologics Manufacturing Facility,Vacaville,California | 9.37% | 1.20bn |
Synaffix BV | -7.38% | 171.01m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum AB (publ) | 1.94bn | 179.75m | 8.43bn | 1.75k | 45.82 | 2.69 | 18.09 | 4.34 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Qiagen NV | 1.79bn | 310.55m | 8.80bn | 5.97k | 28.41 | 2.52 | 17.69 | 4.92 | 1.42 | 1.42 | 8.15 | 15.96 | 0.3169 | 1.93 | 5.38 | 305,504.30 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Ipsen SA | 3.24bn | 605.34m | 9.83bn | 5.33k | 16.18 | 2.59 | 10.47 | 3.03 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
Recordati Industria Chmc Frmctc SpA | 2.10bn | 381.45m | 10.33bn | 4.46k | 26.77 | 5.71 | 19.49 | 4.92 | 1.88 | 1.88 | 10.35 | 8.82 | 0.5177 | 1.67 | 4.53 | 480,087.10 | 9.41 | 11.67 | 12.13 | 15.02 | 67.82 | 70.43 | 18.18 | 21.45 | 0.9518 | 7.21 | 0.4883 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
Eurofins Scientific SE | 6.39bn | 506.66m | 10.84bn | 61.80k | 21.94 | 2.17 | 9.76 | 1.70 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
BioMerieux SA | 3.60bn | 350.79m | 11.52bn | 14.65k | 32.98 | 3.13 | 19.06 | 3.20 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
Sandoz Group AG | -100.00bn | -100.00bn | 13.54bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
Genmab A/S | 2.34bn | 716.59m | 17.41bn | 2.29k | 24.19 | 4.02 | -- | 7.46 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
argenx SE | 1.28bn | -298.24m | 20.27bn | 1.15k | -- | -- | -- | 15.82 | -5.25 | -5.25 | 22.54 | -- | -- | -- | -- | 1,137,778.00 | -- | -17.65 | -- | -19.79 | 89.87 | -- | -23.28 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
UCB SA | 5.15bn | 336.46m | 22.66bn | 9.08k | 67.45 | 2.51 | 22.34 | 4.40 | 1.76 | 1.76 | 26.91 | 47.30 | 0.3345 | 1.76 | 4.63 | 578,223.10 | 2.18 | 5.03 | 2.67 | 6.28 | 67.50 | 72.21 | 6.53 | 12.66 | 0.9224 | 3.14 | 0.2530 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
Bayer AG | 46.73bn | -2.88bn | 27.65bn | 99.72k | -- | 0.856 | 3.78 | 0.5917 | -2.99 | -2.99 | 48.49 | 33.52 | 0.3951 | 1.43 | 4.85 | 477,693.20 | -2.44 | -1.79 | -3.34 | -2.38 | 58.54 | 59.02 | -6.18 | -4.80 | 0.8015 | 3.40 | 0.5764 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
Haleon PLC | 12.83bn | 1.24bn | 34.19bn | 24.00k | 28.07 | -- | 47.17 | 2.67 | 0.1168 | 0.1168 | 1.21 | -- | -- | -- | -- | 468,125.00 | -- | -- | -- | -- | 61.94 | -- | 10.12 | -- | -- | 7.85 | -- | -- | 4.09 | -- | -1.04 | -- | -- | -- |
Lonza Group AG | 6.72bn | 654.00m | 39.20bn | 18.00k | 59.37 | 4.02 | 31.90 | 5.84 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 05 Apr 2024 | 2.56m | 3.44% |
Norges Bank Investment Managementas of 12 Apr 2024 | 2.23m | 2.99% |
UBS Asset Management Switzerland AGas of 02 Apr 2024 | 1.85m | 2.49% |
BlackRock Fund Advisorsas of 30 Apr 2024 | 1.20m | 1.61% |
Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 1.09m | 1.46% |
BlackRock Investment Management (UK) Ltd.as of 31 Mar 2024 | 941.38k | 1.26% |
Invesco Advisers, Inc.as of 31 Mar 2024 | 887.74k | 1.19% |
BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 863.43k | 1.16% |
Schroder Investment Management Ltd.as of 29 Feb 2024 | 856.94k | 1.15% |
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 825.45k | 1.11% |